Last month, Resolve to Save Lives released its “Epidemics that Didn’t Happen” report, celebrating six successful outbreak responses in 2023 and demonstrating the profound impact of sustained investment in preparedness. See here: resolvetosavelives.org/about/press/ne…

Today we announced our second quarter 2024 financial results. Join our management team for a conference call and webcast today at 4:30pm ET as they provide company highlights. Learn more: investor.siga.com/investors/news…

The #Olympic buzz is sizzling in Paris! Keep #mpox and STIs out of your medal count. Learn more from CDC: cdc.gov/poxvirus/mpox/…

We are excited to welcome Ed O’Connor as our new Chief Information Officer. With nearly three decades of experience spearheading operational efficiency and technological innovation, Ed will play a pivotal role in overseeing all #IT activities at our company.

As champions emerge from the #Olympics, let’s also remain victorious against #mpox! Let's continue to prioritize health and safety, not just during the Olympics, but every day. Learn more from World Health Organization (WHO): who.int/news-room/fact…

The World Health Organization (WHO) has declared #mpox a #publichealth emergency of international concern (#PHEIC), triggered by a major outbreak of the viral infection in the DRC and its expansion to nearby countries.

Today NIAID News announced topline results from a preliminary analysis of the PALM 007 clinical trial evaluating our investigational drug for the potential treatment of #mpox in the Democratic Republic of the Congo. See our press release: investor.siga.com/investors/news…

Listen to our Executive Vice President and Chief Medical Officer, @DrJayVarma , discuss the initial results from the PALM 007 clinical trial in this video: siga.com/palm007study

Today we announced a new contract with the Department of Defense 🇺🇸 for the procurement of approximately $9 million of our antiviral drug, representing the third procurement contract award from the DOD in the past three years. See our press release: investor.siga.com/investors/news…

Following World Health Organization (WHO)’s #PHEIC declaration, pharmaphorum spoke with our EVP and CMO @DrJayVarma about the clade 1b #mpox strain, available vaccines & treatments, the initial results from the PALM 007 study, and the criticality of pandemic preparedness. See here: pharmaphorum.com/rd/not-if-when…

The #COVID19 pandemic highlighted the need to upgrade systems for #infectiousdisease surveillance, forecasting, and modeling. Learn more in this Frontiers - Public Health publication: frontiersin.org/journals/publi… @DrJayVarma

Recently World Health Organization (WHO) launched a global Strategic Preparedness and Response Plan to stop outbreaks of human-to-human transmission of #mpox through coordinated global, regional, and national efforts. See here: who.int/news/item/26-0…

Featuring insights from our EVP and CMO, Dr. Jay K. Varma, this The New York Times article explores the escalating #mpox epidemic, the challenges in managing the outbreak, and the critical need for a unified global response. See here: nytimes.com/2024/08/15/hea…

In light of World Health Organization (WHO)’s recent declaration of #mpox as a PHEIC, it is essential to understand what mpox is and how it affects individuals. As we work together to mitigate the impact of this disease, learn more about mpox prevention and treatment: who.int/news-room/fact… #MpoxAwareness

As #mpox spreads rapidly, nature spoke with #infectiousdisease specialists to explore how this current emergency compares to the global outbreak of 2022 and how the clade Ib strain differs from the clade II strain that caused the earlier outbreak. nature.com/articles/d4158…

In this JAMA publication, Johns Hopkins Center for Health Security Senior Scholars Caitlin Rivers, Crystal Watson, DrPH, & @alexandraphelan discuss the resurgence of #mpox and emphasize the urgent need for countries to act swiftly in response to this international call for action: jamanetwork.com/journals/jama/…